Nevro logo

NevroNYSE: NVRO

Profile

Sector:

Healthcare

Country:

United States

IPO:

06 November 2014

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$161.50 M
-95%vs. 3y high
50%vs. sector
-vs. 3y high
-vs. sector
-94%vs. 3y high
30%vs. sector
-95%vs. 3y high
11%vs. sector

Price

after hours | Tue, 19 Nov 2024 23:20:14 GMT
$4.31+$0.01(+0.23%)

Dividend

No data over the past 3 years
$96.91 M$100.02 M
$96.91 M-$15.34 M

Analysts recommendations

Institutional Ownership

NVRO Latest News

Nevro Stock May Gain on the CE Mark Certification for HFX iQ
zacks.com15 November 2024 Sentiment: POSITIVE

NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025.

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
prnewswire.com15 November 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif. , Nov. 15, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on November 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 37,726 shares of Nevro's common stock to 24 new non-executive employees to induce them to accept employment with Nevro.

Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally
prnewswire.com12 November 2024 Sentiment: POSITIVE

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* REDWOOD CITY, Calif. , Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received CE Mark Certification in Europe for its HFX iQ™ spinal cord stimulation (SCS) system.

Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y
zacks.com12 November 2024 Sentiment: NEUTRAL

NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.

Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates
zacks.com11 November 2024 Sentiment: POSITIVE

Nevro (NVRO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.65 per share a year ago.

Nevro Reports Third-Quarter 2024 Financial Results
prnewswire.com11 November 2024 Sentiment: POSITIVE

Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif. , Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance.

New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy
prnewswire.com29 October 2024 Sentiment: POSITIVE

Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif. , Oct. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research  demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy (PDN) and Type 2 diabetes who received 10 kHz high-frequency spinal cord stimulation (SCS) therapy.1 Globally, the number of people with diabetes has quadrupled in the last two decades2, and PDN impacts up to 25% of all people with diabetes.3 PDN can have significant impacts on the quality of life for people living with this condition, with symptoms like numbness, tingling/paresthesia, loss of protective sensation, impaired balance, and reduced response to sensory stimuli.4 Patients typically manage PDN with oral pain medications, but the efficacy of these medications is relatively low and can result in intolerable side effects.5 As a result, people with PDN suffer from significantly reduced health-related quality of life (HRQoL), impaired functionality and other comorbidities like sleep disorders, depression, and anxiety.6 The analysis evaluated 144 patients with Type 2 diabetes and refractory PDN who received 10 kHz SCS therapy during the SENZA-PDN randomized controlled trial (RCT), the largest RCT to evaluate SCS to treat PDN.

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
prnewswire.com16 October 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif. , Oct. 16, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on October 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,088 shares of Nevro's common stock to five new non-executive employees to induce them to accept employment with Nevro.

Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024
prnewswire.com10 October 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif. , Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024.

Here's Why you Should Retain Nevro Stock in Your Portfolio Now
zacks.com26 September 2024 Sentiment: POSITIVE

Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock.

What type of business is Nevro?

Nevro Corp. is a global medical equipment company focused on providing innovative products that improve the quality of life for patients suffering from chronic pain. The company has developed the Senza spinal cord stimulation system, a scientifically based neuromodulation platform for treating chronic pain, and has also launched the latest product platform, Senza Omnia. The company launched Senza in the United States in May 2015, in some European countries since November 2010, and in Australia since August 2011. Currently, Senza is covered by all major insurance companies, and the patented hf10 therapy without sensory disturbances outperforms traditional spinal cord stimulation therapy, with hf10 therapy being nearly twice as successful in treating back pain and 1.5 times more successful in treating leg pain compared to traditional spinal cord stimulation therapy.

What sector is Nevro in?

Nevro is in the Healthcare sector

What industry is Nevro in?

Nevro is in the Medical Devices industry

What country is Nevro from?

Nevro is headquartered in United States

When did Nevro go public?

Nevro initial public offering (IPO) was on 06 November 2014

What is Nevro website?

https://nevro.com

Is Nevro in the S&P 500?

No, Nevro is not included in the S&P 500 index

Is Nevro in the NASDAQ 100?

No, Nevro is not included in the NASDAQ 100 index

Is Nevro in the Dow Jones?

No, Nevro is not included in the Dow Jones index

When was Nevro the previous earnings report?

No data

When does Nevro earnings report?

The next expected earnings date for Nevro is 21 February 2025